Beta-Blockers in the Management of Hypertension and/or Chronic Kidney Disease

International Journal of Hypertension

Volumn 2014, Issue , 2014, Pages

  Tomiyama, Hirofumi ^a   Yamashina, Akira ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CANDESARTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; NEBIVOLOL; TELMISARTAN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; CORRELATIONAL STUDY; DEPRESSION; DRUG EFFICACY; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HUMAN; HYPERTENSION; MEDICATION THERAPY MANAGEMENT; META ANALYSIS (TOPIC); METABOLIC DISORDER; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; SUDDEN CARDIAC DEATH; SYSTOLIC HEART FAILURE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 84895802580     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.1155/2014/919256     Document Type: Review

References (55)

1. Wiysonge C. S., Bradley H., Mayosi B. M., Maroney R., Mbewu A., Opie L. H., Volmink J., Beta-blockers for hypertension. Cochrane Database of Systematic Reviews 2007 1 CD002003 2-s2.0-34248198272 10.1002/14651858.CD002003.pub2
2. Wiysonge C. S., Bradley H., Mayosi B. M., Maroney R., Mbewu A., Opie L. H., Volmink J., Beta-blockers for hypertension. Cochrane Database of Systematic Reviews 2012 8 CD002003 2-s2.0-34248198272 10.1002/14651858.CD002003.pub3
3. Lindholm L. H., Carlberg B., Samuelsson O., Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. The Lancet 2005 366 9496 1545 1553 2-s2.0-27544463207 10.1016/S0140-6736(05)67573-3
4. Prichard B. N. C., The second Lilly Prize Lecture, University of Newcastle, July 1977. β -Adrenergic receptor blockade in hypertension, past, present and future. British Journal of Clinical Pharmacology 1978 5 5 379 399 2-s2.0-0018090462 10.1111/j.1365-2125.1978.tb01644.x
5. Hjalmarson Å., Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter? Basic Research in Cardiology 2000 95 supplement 1 I41 I45 2-s2.0-0034537884
6. Rinfret S., Abrahamowicz M., Tu J., Humphries K., Eisenberg M. J., Richard H., Austin P. C., Pilote L., A population-based analysis of the class effect of β -blockers after myocardial infarction. American Heart Journal 2007 153 2 224 230 2-s2.0-33846233408 10.1016/j.ahj.2006.11.008
7. Carlberg B., Samuelsson O., Lindholm L. H., Atenolol in hypertension: is it a wise choice? The Lancet 2004 364 9446 1684 1689 2-s2.0-13844314822 10.1016/S0140-6736(04)17355-8
8. De Caterina A. R., Leone A. M., The role of beta-blockers as first-line therapy in hypertension. Current Atherosclerosis Reports 2011 13 2 147 153 2-s2.0-79955903804 10.1007/s11883-010-0157-9
9. Elliott W. J., Childers W. K., Should β blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities? Current Cardiology Reports 2011 13 6 507 516 2-s2.0-81255210302 10.1007/s11886-011-0216-z
10. Dahlöf B., Sever P. S., Poulter N. R., Wedel H., Beevers D. G., Caulfield M., Collins R., Kjeldsen S. E., Kristinsson A., McInnes G. T., Mehlsen J., Nieminen M., O'Brien E., Östergren J., Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet 2005 366 9489 895 906 2-s2.0-24644443331 10.1016/S0140-6736(05)67185-1
11. Webb A. J., Fischer U., Mehta Z., Rothwell P. M., Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. The Lancet 2010 375 9718 906 915 2-s2.0-77749282912 10.1016/S0140-6736(10)60235-8
12. Rothwell P. M., Howard S. C., Dolan E., O'Brien E., Dobson J. E., Dahlöf B., Poulter N. R., Sever P. S., Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. The Lancet Neurology 2010 9 5 469 480 2-s2.0-77950629667 10.1016/S1474-4422(10)70066-1
13. Neutel J. M., Schnaper H., Cheung D. G., Graettinger W. F., Weber M. A., Antihypertensive effects of β -blockers administered once daily: 24-hour measurements. American Heart Journal 1990 120 1 166 171 2-s2.0-0025294964 10.1016/0002-8703(90)90174-V
14. Morgan T. O., Anderson A., Different drug classes have variable effects on blood pressure depending on the time of day. American Journal of Hypertension 2003 16 1 46 50 2-s2.0-0037235627 10.1016/S0895-7061(02)03081-9
15. Sarafidis P., Bogojevic Z., Basta E., Kirstner E., Bakris G. L., Comparative efficacy of two different beta-blockers on 24-hour blood pressure control. The Journal of Clinical Hypertension 2008 10 2 112 118 2-s2.0-42049104616 10.1111/j.1751-7176.2008.08021.x
16. Neutel J. M., Smith D. H. G., Ram C. V. S., Kaplan N. M., Papademetriou V., Fagan T. C., Lefkowitz M. P., Kazempour M. K., Weber M. A., Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. The American Journal of Medicine 1993 94 2 181 187 2-s2.0-0027502270 10.1016/0002-9343(93)90181-N
17. Tomiyama H., Yamashina A., Non-invasive vascular function tests: their pathophysiological background and clinical application. Circulation Journal 2010 74 1 24 33 2-s2.0-75149157048 10.1253/circj.CJ-09-0534
18. Vlachopoulos C., Aznaouridis K., O'Rourke M. F., Safar M. E., Baou K., Stefanadis C., Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. European Heart Journal 2010 31 15 1865 1871 2-s2.0-77954814318 10.1093/eurheartj/ehq024
19. Dhakam Z., McEniery C. M., Yasmin Y., Cockcroft J. R., Brown M. J., Wilkinson I. B., Atenolol and eprosartan: dfferential effects on central blood pressure and aortic pulse wave velocity. American Journal of Hypertension 2006 19 2 214 219 2-s2.0-33344461687 10.1016/j.amjhyper.2005.08.007
20. Manisty C. H., Hughes A. D., Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. British Journal of Clinical Pharmacology 2013 75 1 79 92 10.1111/j.1365-2125.2012.04342.x
21. Fagard R. H., Celis H., Thijs L., Wouters S., Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009 54 5 1084 1091 2-s2.0-70449730792 10.1161/HYPERTENSIONAHA.109.136655
22. Kampus P., Serg M., Kals J., Zagura M., Muda P., Karu K., Zilmer M., Eha J., Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension 2011 57 6 1122 1128 2-s2.0-79956343749 10.1161/HYPERTENSIONAHA.110.155507
23. Gapon L. I., Prilepova A. A., Tsygol'nik M. D., Effect of nebivolol on parameters of cerebral haemodynanics and 24-hour blood pressure profile in patients with arterial hypertension. Kardiologiya 2005 45 10 18 22 2-s2.0-33645452777
24. Fountoulaki K., Dimopoulos V., Giannakoulis J., Zintzaras E., Triposkiadis F., Left ventricular mass and mechanics in mild-to-moderate hypertension: effect of nebivolol versus telmisartan. American Journal of Hypertension 2005 18 2, part 1 171 177 2-s2.0-14744302893 10.1016/j.amjhyper. 2004.08.039
25. Shahin Y., Khan J. A., Samuel N., Chetter I., Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials. Atherosclerosis 2011 216 1 7 16 2-s2.0-79955546830 10.1016/j.atherosclerosis.2011.02.044
26. Bank A. J., Kelly A. S., Thelen A. M., Kaiser D. R., Gonzalez-Campoy J. M., Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. American Journal of Hypertension 2007 20 7 777 783 2-s2.0-34250638587 10.1016/j.amjhyper.2007.01.019
27. Pasini A. F., Garbin U., Stranieri C., Boccioletti V., Mozzini C., Manfro S., Pasini A., Cominacini M., Cominacini L., Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. American Journal of Hypertension 2008 21 11 1251 1257 2-s2.0-54249107160 10.1038/ajh.2008.260
28. Messerli F. H., Bangalore S., Julius S., Risk/benefit assessment of β -blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 2008 117 20 2706 2715 2-s2.0-47649085694 10.1161/CIRCULATIONAHA.107.695007
29. Bakris G. L., Fonseca V., Katholi R. E., McGill J. B., Messerli F. H., Phillips R. A., Raskin P., Wright J. T., Oakes R., Lukas M. A., Anderson K. M., Bell D. S. H., Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. The Journal of the American Medical Association 2004 292 18 2227 2236 2-s2.0-7744237066 10.1001/jama.292.18.2227
30. Messerli F. H., Bell D. S. H., Fonseca V., Katholi R. E., McGill J. B., Phillips R. A., Raskin P., Wright J. T. Jr., Bangalore S., Holdbrook F. K., Lukas M. A., Anderson K. M., Bakris G. L., Body weight changes with β -blocker use: results from GEMINI. The American Journal of Medicine 2007 120 7 610 615 2-s2.0-34250900379 10.1016/j.amjmed.2006.10.017
31. Kohro T., Hayashi D., Yamazaki T., Nagai R., Beta-blocker prescription among Japanese cardiologists and its effect on various outcomes. Circulation Journal 2010 74 5 962 969 2-s2.0-77951715520 10.1253/circj.CJ-09-0613
32. Wikstrand J., Warnold I., Tuomilehto J., Olsson G., Barber H. J., Eliasson K., Elmfeldt D., Jastrup B., Karatzas N. B., Leer J., Marchetta F., Ragnarsson J., Robitaille N.-M., Valkova L., Wesseling H., Berglund G., Metoprolol versus thiazide diuretics in hypertension: morbidity results from the MAPHY study. Hypertension 1991 17 4 579 588 2-s2.0-0025876237 10.1161/01.HYP.17.4.579
33. Turnbull F., Neal B., Ninomiya T., Algert C., Arima H., Barzi F., Bulpitt C., Chalmers J., Fagard R., Gleason A., Heritier S., Li N., Perkovic V., Woodward M., MacMahon S., Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger people: meta-analysis of randomised trials. British Medical Journal 2008 336 7653 1121 1123 2-s2.0-44349101152 10.1136/bmj.39548.738368.BE
34. Luijendijk H. J., van den Berg J. F., Hofman A., Tiemeier H., Stricker B. H. C., β -blockers and the risk of incident depression in the elderly. Journal of Clinical Psychopharmacology 2011 31 1 45 50 2-s2.0-78651285744 10.1097/JCP.0b013e31820482c4
35. Bangalore S., Sawhney S., Messerli F. H., Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. Journal of the American College of Cardiology 2008 52 18 1482 1489 2-s2.0-53949086528 10.1016/j.jacc.2008.06.048
36. Jouven X., Empana J.-P., Schwartz P. J., Desnos M., Courbon D., Ducimetière P., Heart-rate profile during exercise as a predictor of sudden death. The New England Journal of Medicine 2005 352 19 1951 1958 2-s2.0-18344367496 10.1056/NEJMoa043012
37. Tomiyama H., Hashimoto H., Tanaka H., Matsumoto C., Odaira M., Yamada J., Yoshida M., Shiina K., Nagata M., Yamashina A., Synergistic relationship between changes in the pulse wave velocity and changes in the heart rate in middle-aged Japanese adults: a prospective study. Journal of Hypertension 2010 28 4 687 694 2-s2.0-78650774397 10.1097/HJH.0b013e3283369fe8
38. KDIGO Blood Pressure Work Group, KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney International Supplements 2012 2 5, supplement 337 414
39. Verbeke F., Lindley E., Van Bortel L., Vanholder R., London G., Cochat P., Wiecek A., Fouque D., Van Biesen W., A European Renal Best Practice (ERBP) position statement on the Kidney Disease: improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Non-dialysis-dependent Chronic Kidney Disease: an endorsement with some caveats for real-life application. Nephrology Dialysis Transplantation 2013 10.1093/ndt/gft321
40. Petras D., Koutroutsos K., Kordalis A., Tsioufis C., Stefanadis C., The role of sympathetic nervous system in the progression of chronic kidney disease in the era of catheter based sympathetic renal denervation. Current Clinical Pharmacology 2013 8 3 197 205
41. Zoccali C., Mallamaci F., Parlongo S., Cutrupi S., Benedetto F. A., Tripepi G., Bonanno G., Rapisarda F., Fatuzzo P., Seminara G., Cateliotti A., Stancanelli B., Malatino L. S., Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002 105 11 1354 1359 2-s2.0-0037133633 10.1161/hc1102.105261
42. Ptinopoulou A. G., Pikilidou M. I., Lasaridis A. N., The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review. Hypertension Research 2013 36 2 91 101 10.1038/hr.2012.157
43. Wright R. S., Reeder G. S., Herzog C. A., Albright R. C., Williams B. A., Dvorak D. L., Miller W. L., Murphy J. G., Kopecky S. L., Jaffe A. S., Acute myocardial infarction and renal dysfunction: a high-risk combination. Annals of Internal Medicine 2002 137 7 563 570 2-s2.0-0036788828 10.7326/0003-4819-137-7- 200210010-00007
44. Abbott K. C., Trespalacios F. C., Agodoa L. Y., Taylor A. J., Bakris G. L., β -blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Archives of Internal Medicine 2004 164 22 2465 2471 2-s2.0-10344266474 10.1001/archinte.164.22.2465
45. Kidney Disease Outcomes Quality Initiative (K/DOQI), K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. American Journal of Kidney Diseases 2004 43 supplement 1 5 S1 S290
46. Bakris G. L., Copley J. B., Vicknair N., Sadler R., Leurgans S., Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney International 1996 50 5 1641 1650 2-s2.0-0029961207 10.1038/ki.1996.480
47. Holman R., Turner R., Stratton I., Cull C., Frighi V., Manley S., Matthews D., Neil A., Kohner E., Wright D., Hadden D., Fox C., Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. British Medical Journal 1998 317 7160 713 720 2-s2.0-0032511601 10.1136/bmj.317.7160.713
48. Wright J. T. Jr., Bakris G., Greene T., Agodoa L. Y., Appel L. J., Charleston J., Cheek D., Douglas-Baltimore J. G., Gassman J., Glassock R., Hebert L., Jamerson K., Lewis J., Phillips R. A., Toto R. D., Middleton J. P., Rostand S. G., Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. The Journal of the American Medical Association 2002 288 19 2421 2431 2-s2.0-0037145856 10.1001/jama.288.19.2421
49. Fassbinder W., Quarder O., Waltz A., Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentre randomised study. International Journal of Clinical Practice 1999 53 7 519 522 2-s2.0-0032743019
50. Bakris G. L., Weir M. R., Secic M., Campbell B., Weis-McNulty A., Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney International 2004 65 6 1991 2002 2-s2.0-2442703942 10.1111/j.1523-1755.2004.00620.x
51. Levin A., Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Seminars in Dialysis 2003 16 2 101 105 2-s2.0-0042073223 10.1046/j.1525-139X.2003.16025.x
52. Green D., Roberts P. R., New D. I., Kalra P. A., Sudden cardiac death in hemodialysis patients: an in-depth review. American Journal of Kidney Diseases 2011 57 6 921 929 2-s2.0-79956352144 10.1053/j.ajkd.2011.02.376
53. Badve S. V., Roberts M. A., Hawley C. M., Cass A., Garg A. X., Krum H., Tonkin A., Perkovic V., Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. Journal of the American College of Cardiology 2011 58 11 1152 1161 2-s2.0-80052365390 10.1016/j.jacc.2011.04.041
54. Tangri N., Shastri S., Tighiouart H., Beck G. J., Cheung A. K., Eknoyan G., Sarnak M. J., β -blockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO study. American Journal of Kidney Diseases 2011 58 6 939 945 2-s2.0-81755161496 10.1053/j.ajkd.2011.06.024
55. Ritz E., Rump L. C., Do β -blockers combined with RAS inhibitors make sense after all to protect against renal injury? Current Hypertension Reports 2007 9 5 409 414 2-s2.0-36849011458 10.1007/s11906-007-0075-6